Christopher Brown, MD
Family Medicine · Willard, OHNPI 1518971563
Payments from drug & device makers
Across 92 payments — averaging $16.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$225
- Johnson & Johnson$171
- Novo Nordisk$156
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$137
- Pfizer$118
- GSK$117
- plus $559 from 17 others
What the payments were for
- Speaking & faculty fees$352%
- Food & beverage$1,44097%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 10 | $225 |
| Johnson & Johnson | 5 | $171 |
| Novo Nordisk | 4 | $156 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $137 |
| Pfizer | 19 | $118 |
| GSK | 10 | $117 |
| Astellas Pharma US Inc | 4 | $88 |
| Amarin Pharma, Inc. | 5 | $82 |
| Sanofi-aventis U.S. LLC | 3 | $71 |
| Teva Pharmaceuticals USA, Inc. | 4 | $55 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Amgen | 2 | $36 |
| AbbVie(2 entities) | 2 | $31 |
| Lilly USA, LLC | 2 | $29 |
| Mylan Specialty L.p. | 1 | $16 |
| Merck | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Medtronic | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Cranial Technologies, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,481 in reported general payments places this provider in the 70th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 166 | $146,346 |
| OzempicSemaglutide | 107 | $130,126 |
| Enbrel SureclickEtanercept | 15 | $113,505 |
| JardianceEmpagliflozin | 95 | $95,305 |
| TrulicityDulaglutide | 62 | $76,871 |
| JanuviaSitagliptin Phosphate | 31 | $43,275 |
| XareltoRivaroxaban | 36 | $40,901 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $29,040 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $22,078 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $20,656 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $20,134 |
| FarxigaDapagliflozin Propanediol | 18 | $19,441 |
| MounjaroTirzepatide | 17 | $18,879 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $18,100 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 80 | $12,061 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $118 | $146,346166 claims |
| Novo NordiskOzempic | $156 | $130,126107 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $29 | $95,75079 claims |
| MerckJanuvia, Janumet Xr | $15 | $63,93252 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $117 | $53,431101 claims |
| Johnson & JohnsonXarelto | $171 | $40,90136 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $225 | $32,54047 claims |
| AbbVieLinzess | $31 | $11,62016 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $14 | $6,27713 claims |
| Astellas Pharma US IncMyrbetriq | $88 | $5,36512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Willard
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.